GSK starts phase 3 trial of new Type 2 diabetes drug Syncria
LONDON British drug maker GlaxoSmithKline has started a phase 3 trial of a new treatment for Type 2 diabetes, the company announced Tuesday.
GSK said the trial would judge the efficacy, safety and tolerability of Syncria (albiglutide), which belongs to the class known as glucagon-like peptide 1 agonists. The trial will include more than 4,000 patients.
“Despite continued advances in diabetes treatment, this devastating disease continues to increase at an alarming pace worldwide,” GSK SVP biopharm development Carlo Russo said in a statement. “Albiglutide is a novel biological currently being investigated to determine its potential to help people control their blood sugar, particularly when oral treatments alone may not provide an adequate response.”
Boston bans tobacco sales in retail pharmacies
A few months after San Francisco drug stores cleared their inventories of anything with tobacco, a city on the opposite side of the country passed a similar ban. Boston has banned tobacco sales in retail pharmacies as well, but its ban covers all stores that operate pharmacies, not just drug stores.
While Walgreens sued San Francisco over its ban, alleging discrimination, it has accepted the one in Boston without complaint. Health officials in San Francisco might want to pay a little attention to what’s happening in Boston because it could help them save a few pennies on legal fees.
Pharmacy’s role in health reform
WASHINGTON “We must all hang together, or most assuredly we will all hang separately.” That dictum, attributed to Ben Franklin, could apply to the increasingly urgent campaign by a wide-ranging assortment of pharmacy and retail advocacy groups to speak with one voice in policymaking circles. In the midst of an economic crisis, a dysfunctional healthcare system in dire need of new cost-saving solutions and a revolution in technology and communications, pharmacy leaders from every practice setting are acutely aware of the need for a united front.
That goes double when making pharmacy’s case for a larger and fully integrated role in the healthcare system of the future. When the leaders of the National Association of Chain Drug Stores, the National Community Pharmacists Association and other organizations appeal to lawmakers in Congress amid debates about health reform and health information technology, they’re also making their case in the court of public opinion.
Dealing with congressional staffers on Capitol Hill is just as challenging. Given the complexity of such issues as fair pharmacy reimbursement, patient privacy, health IT, medication therapy management and coordination of care, it’s essential that the disparate and sometimes competing stakeholders that represent all aspects of pharmacy put aside their differences and “hang together.”
“The future direction of the industry hinges on the willingness of NACDS members to engage in the public policy debates of the day, since affecting our short- and long-term future is the primary reason we all choose to participate in associations like this one,” said NACDS chairman and Katz Group North America CEO Andy Giancamilli at the recent NACDS Regional Chain Conference. “But now we need even more members to engage in powering the NACDS advocacy engine.”